Hypoxic–ischemic (HI) brain injury in infants is a leading cause of lifelong disability. We report a novel pathway mediating oxidative brain injury after hypoxia–ischemia in which C1q plays a central role. Neonatal mice incapable of classical or terminal complement activation because of C1q or C6 deficiency or pharmacologically inhibited assembly of membrane attack complex were subjected to hypoxia–ischemia. Only C1q-deficient mice exhibited neuroprotection coupled with attenuated oxidative brain injury. This was associated with reduced production of reactive oxygen species (ROS) in C1q+/− brain mitochondria and preserved activity of the respiratory chain. Compared with C1q+/+ neurons, cortical C1q−/− neurons exhibited resistance to oxygen–glucose deprivation. However, postischemic exposure to exogenous C1q increased both mitochondrial ROS production and mortality of C1q−/− neurons. This C1q toxicity was abolished by coexposure to antioxidant Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). Thus, the C1q component of complement, accelerating mitochondrial ROS emission, exacerbates oxidative injury in the developing HI brain. The terminal complement complex is activated in the HI neonatal brain but appeared to be nonpathogenic. These findings have important implications for design of the proper therapeutic interventions against HI neonatal brain injury by highlighting a pathogenic priority of C1q-mediated mitochondrial oxidative stress over the C1q deposition-triggered terminal complement activation.

Introduction

Accumulating evidence indicate that complement (C) activation contributes to ischemia–reperfusion injury in different organs (Pedersen et al., 2004; Arumugam et al., 2006). We have reported that neonatal mice with genetic deletion of C1q, the initial component of classical C pathway activation, were protected against hypoxic–ischemic (HI) brain injury (Ten et al., 2005). C1q is essential for activation of the classical C pathway, which results in assembly of cytotoxic membrane attack complex (MAC) (Trouw et al., 2008). In the heart and kidney, an ischemic insult results in robust activation of classical C pathway and deposition of MAC in the injured tissue, suggesting a pathogenic role for the terminal C complex in tissue damage (Vakeva et al., 1998; Zhou et al., 2000; Yamada et al., 2004). The evidence for a deleterious role of terminal C activation in perinatal cerebral HI injury is controversial. Systemic C depletion with cobra venom factor significantly attenuated HI brain damage in neonatal rats. However, the cerebral expression of C9, a marker for MAC assembly, in the C-depleted rats was similar to that in the vehicle-treated littermates (Cowell et al., 2003), arguing against a pathogenic role of MAC in HI injury. In contrast, an association between cerebral C9 deposition and the severity of brain injury has been reported in HI rats and asphyxiated infants (Figueroa et al., 2005; Schultz et al., 2005). Pretreatment with exogenous C9 exacerbated HI brain injury in immature rats deficient in C9 (Inm et al., 2002). Furthermore, human cultured neurons incubated with anti-CDS9 antibodies were susceptible to MAC-driven cytolysis after spontaneous activation of the classical C pathway (Singhrao et al., 2000). This suggests that C1q mediates HI brain injury via classical C pathway activation resulting in MAC-driven exacerbation of cell damage during reperfusion.

It has been shown that incubation of cultured cortical neurons with human C1q induced a lethal oxidative stress (Luo et al., 2003). Given that mitochondria are primary source of reactive oxygen species (ROS), we hypothesized that C1q may exacerbate HI brain damage by affecting mitochondrial ROS generation.

In this study, we tested two alternative hypotheses: (1) neonatal HI brain injury is mediated by C1q-dependent terminal C activation or (2) C1q directly (independently from C activation pathway) exacerbates HI brain injury by potentiating the severity of mitochondria-mediated oxidative stress.
Materials and Methods

Mice. C1qκ knock-out (C1qκ−/−), C6-deficient (C6−/−) mice back-crossed into C57BL/6 strain for 10 and 5 generations (Botto et al., 1998; Morgan et al., 2006) and wild-type (WT) mice (C57BL/6) purchased from The Jackson Laboratory) were bred in the animal facility of Columbia University. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Columbia University.

Induction of unilateral hypoxia–ischemia. We used the Rice–Vannucci model of HI brain injury adapted to postnatal day 9 (P9) to P10 neonatal mice (Ten et al., 2003, 2004). The model consisted of a permanent ligation of the right carotid artery followed by hypoxic exposure. Briefly, surgical intervention was performed under isoflurane anesthesia. At 1.5 h of recovery, pups were exposed to hypoxia (8% O2, balanced N2) for 15 min. The ambient temperature during hypoxia was maintained at 37.0–37.5°C by placing the hypoxic chamber in a neonatal isolate (Airshield). After hypoxic exposure, pups were returned to their dams. To minimize a temperature-related variability in the extent of brain injury, during the initial 12 h of reperfusion, mice were kept in an isoelette at the ambient t = 32°C. In adult male mice, hypoxia–ischemia was produced as described above, except the ambient temperature during hypoxia was maintained at 35.5–36°C, and the duration of hypoxia was extended to 25 min. The modulation of hypoxic duration with the age was shown to produce a similar degree of injury in neonatal or juvenile or adult mice with minimal changes in mortality (Lafemina et al., 2006; Zhu et al., 2009). At 24 h of reperfusion, mice were killed by decapitation, and brains were harvested, sectioned into 1-mm-thick coronal slices, and stained with 2% triphenyl-tetrazolium chloride (TTC). TTC is oxidized only by metabolically active mitochondrial dehydrogenases converting TTC into a red-colored formazan (Schnizel et al., 2005). Digital images of infarcted (pale white) and viable (red) areas of brains were traced (Adobe Photoshop 4.0.1) and analyzed (NIH Image 1.62) by an investigator “blinded” to a genotype identity. The extent of brain injury (direct infarct volume) was expressed as a percentage of the infarcted hemisphere ipsilateral to the carotid artery ligation.

C1q and MAC in HI injury. To investigate the role of C1q and MAC in HI brain injury, the progenies of C1qκ−/− or C1qκ+/- and C1qκ−/− mating (cohort 1), C1qκ−/− along with age- and strain-matched C6-deficient and WT mice (cohort 2) simultaneously were subjected to hypoxia–ischemia. C1qκ−/− mice are not able to activate terminal C via the classical C activation pathway. The C6−/− mice lack one (C6b) of the components of MAC (C5b–C9) and are not able to assemble a functional terminal C complex (MAC). Therefore, if C1q-dependent (classical pathway) activation of the terminal C complex participates in HI injury, then both C1qκ−/− and C6−/− mice are expected to demonstrate neuroprotection. The extent of cerebral damage was analyzed after C1q genotyping.

C1q genotype. C1qα primers were as follows: mC1q4α/5’, GGCGGCCGTATGCCACAG; mC1q4α/2−, TAACTGGTTCGCTCAGG; Neo3’, GGCGGATCCAAAAGGAG. The deficiency of C6 (C6−/−) in mice was verified functionally by the assessment of C6-dependent hemolytic activity of human serum (Kahab and Mayer, 1961). Briefly, in 500 μl of gelatin Veronal buffer (Sigma–Aldrich), an increasing concentration of serum obtained from P10 naive WT or C6−/− mice was incubated with sensitized sheep erythrocytes (3 × 1011; Sigma–Aldrich) in the presence of human C6-deficient serum (25 μl; Sigma–Aldrich) for 30 min at 37°C. Hemolytic activity of each sample was measured at 412 nm to obtain hemolytic titration curve. Using this curve, the amount of WT mouse (C6−/−) serum (20 μl) that restored 50–60% of hemolytic activity of C6-deficient serum was determined. Then hemolytic activity of serum (20 μl) obtained from randomly selected C6−/− and WT HI mice were compared and expressed as percentage of hemolysis relative to the extent of spontaneous hemolysis (0%) and osmotic hemolysis (100%).

A separate cohort of WT mice was used to determine whether pharmacological inhibition of MAC assembly attenuates the extent of HI brain injury. At 12 h before HI insult, WT mice were pretreated either with mouse-specific IgG-fused soluble CD59 (sCD59) (200 μg, i.p., in 0.15 ml of PBS) or vehicle (0.15 ml of PBS, i.p.) followed by the exposure to HI insult as described previously. At 24 h of reperfusion, brains were examined for the degree of C9 deposition and the extent of HI injury.

sCD59 is a potent primary inhibitor of MAC assembly on cell membranes in mice (Baalsubramanian et al., 2004). Pretreatment with sCD59 has been shown to limit the assembly of MAC (decreased deposition of C9) in the renal tissue after ischemia–reperfusion, and this was associated with attenuation of injury (Yamada et al., 2004).

Extent of C activation. The extent of C activation was assessed by detection of C3-split products and C9 in the post-HI brains. Briefly, at 24 h after HI insult, brains were harvested from randomly selected C1qκ−/−, C1qκ+/- mice and the WT mice pretreated with sCD59 or vehicle, fixed in 4% paraformaldehyde, and incubated with rabbit/anti-rat C9 antibodies or rat/anti-mouse monoclonal antibodies against C3h/C3b/C3c neoepitopes (Hycult Biotechnology). Rabbit/anti-rat C9 antibodies cross-react with mouse C9 and have been used as a marker for MAC assembly and cellular deposition after renal and brain injury in mice (Yamada et al., 2004; Alexander et al., 2005). Nissl and microtubule-associated protein 2 (MAP2) (1:800; Sigma–Aldrich) staining were used to counterstain nucleus and neuronal cytosol. During confocal microscopy (Bio-Rad 2000 laser-scanning device; Nikon E800), the infarcted areas of brain were identified by the regional loss of MAP2 immunoreactivity. The level of immunopositivity for C9 and C3-split products was assessed semi-quantitatively as described previously (Ten et al., 2005). Images of area of interest (ipsilateral and contralateral hemisphere) were captured under identical fluorescence and magnification. Areas (in pixels) positive for C9 and C3-split products were measured using Image-Pro Plus 4.5 (Media Cybernetics). A total of five nonadjacent fields in five cerebral sections (−1 to +1.5 mm in relation to bregma) were analyzed from each mouse. Mean value of immunopositivity (pixels) for C9 and C3-split products obtained from a single mouse was used for data analysis. In addition, the presence of C3d (C3-split product) in the ischemic brains was quantified by Western blot analysis as described previously (Mack et al., 2006). In brief, 50 μg of total protein per sample were denaturated in SDS with reducing agent and run on NuPAGE Novex 12% Bis-Tris Gel (Invitrogen) under reducing conditions. Membranes were incubated with the goat anti-mouse C3d antibody (1:1000; R&D Systems) followed by incubation with horseradish peroxidase (HRP)-conjugated donkey anti-goat secondary antibody (1:20,000). Immunoreactive bands were detected using a chemiluminescence kit (Thermo Fisher Scientific), and membranes were exposed to x-ray film (Eastman Kodak). Blots were scanned and analyzed using NIH ImageJ to quantify relative (normalized to β-actin) expression of C3d. The ratio of C3d optical density between ipsilateral and contralateral hemisphere was used for statistical analysis.

Neuronal C1q genotype and oxygen–glucose deprivation. Cortical neurons were isolated from mouse fetal brains at 16 d of gestation as described previously (Brewer et al., 1993; Takuma et al., 2003). Briefly, the cerebral cortex from WT and C1qκ−/− fetuses was removed, digested with collagenase (1 mg/ml) and trypsin (0.25%), and plated in Neurobasal media supplemented with 2% B27, 0.5 mM glutamine, and 4.4 mM sodium bicarbonate. Isolated cortical neurons in 1 ml of the media were centrifuged (3000 × g, 3 min; at 4°C), and pellets were resuspended in the Neurobasal/B27 media supplemented with 0.5 mM glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. Then cells were seeded in the 24-well plates (Corning Life Sciences) precoated with 50 mg/ml poly-l-lysine (Invitrogen) at a density of 1 × 104 cells per well. After 3–4 d in vitro incubation at 37°C and 5% CO2, neurons were subjected to the oxygen–glucose deprivation (OGD) stress.

OGD challenge. OGD challenge was produced as described previously (Zhang et al., 2003; Benchenane et al., 2005). In brief, the neurons were washed with HBSS, rinsed with PBS, and incubated in glucose-free DMEM media pre bubbled with hypoxic gas mixture (94% N2 plus 6% CO2 at pH 7.4) in the tightly sealed plastic chamber containing anaerobic GasPak EZ Container System and O2 indicator (BD Biosciences). The GasPak EZ system contains a reagent sacchet consisting of inorganic carbonate, activated carbon, ascorbic acid, and water. When the sacchet is removed from the outer wrapper, it is activated by the exposure to air and rapidly reduces the oxygen concentration within the chamber to <1%. The O2 indicator changes color (white to blue) if O2 concentration in the chamber exceeds 1%. The OGD was carried for 4 h at 37°C. After OGD cells were replenished with fresh media and kept at standard (normoxia; 5% CO2 at 37°C) condition for reperfusion. At 20 h of reperfusion,
cellular viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reducing assay. Briefly, cells were washed with HBSS and incubated in the same media containing 5 mg/ml MTT and 10 mM sodium succinate. After 60 min of incubation, the media was removed and cells were rinsed with PBS and dried. The formazan crystals were solubilized with 0.3 ml of 4 mM HCl-isopropanol. The plates were read on the Tecan microplate reader (Infinite M200) at a wavelength of 570 nm.

To examine a direct effect of C1q on cellular survival during reperfusion, C1q$$^+/−$$ neurons were exposed to increasing concentrations (0.035–1.75 μg/ml) of purified human C1q protein (hC1q) produced as described previously (Tenner et al., 1981) or purchased (Quidel). The concentration of C1q in human CSF averages 0.340 μg/ml (Smyth et al., 1994). Given that, after a global cerebral ischemia, C1q is dramatically upregulated leading to a threefold to sixfold increase in C1q-dependent hemolytic activity (Schäfer et al., 2000), we selected hC1q doses representing normal and elevated C1q concentration in CSF, 0.35 to 1.75 μg/ml. Cellular viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 10 mM HRP. The rate of H$$2$$O$$2$$ emission was performed by a fluorescence as described by Griffith (1980) with minor modification. Briefly, to prevent self-oxidation, mitochondria (1.5 mg/ml) were diluted in 5% metaphosphoric acid (1:1). Three working solutions were used as follows: (1) 0.3 mM NADPH (Sigma-Aldrich), 2 mM KH$$2$$PO$$4$$, 5 mM HEPES-KOH, pH 7.2, 5 mM MgCl$$2$$, 0.2 mg/ml BSA, 30 μM P$$2$$, P$$3$$-di(adenosine 5’)-pentaphosphate (Ap$$3$$A) (an inhibitor of adenosyl kinase), 10 mM glutamate, and 5 mM malate at t = 32°C. To initiate the phosphorolyzing reaction (state 3), 100 nmol of ADP was added to the mitochondrial suspension. To achieve a nonphosphorolyzing (uncoupled) acceleration of respiration, 70 μM 2,4-dinitrophenol (DNP) was added at the state 4, after a completion of ADP phosphorylation. Rates of O$$2$$ consumption were expressed in nanomoles of O$$2$$ per milligram of mitochondrial protein (state 4). The respiratory control ratio (RCR) was calculated as the ratio of the state 3 respiration rate to the testing respiration rate (state 4) recorded after the phosphorylation of ADP has been completed.

Measurement of mitochondrial H$$2$$O$$2$$ emission rate. Measurement of mitochondrial H$$2$$O$$2$$ emission rate was performed by a fluorescence assay with Hitachi 7000 spectrofluorometer set at 555 nm excitation and 581 nm emission as described previously (Starkov and Fiskum, 2003).

Briefly, mitochondria (0.05 mg/ml) were placed in 1 ml of respiration buffer with omitted malate/glutamate and Ap$$3$$A, but supplemented with 5 mM succinate, 10 μM Amplex Ultrared (Invitrogen), and 4 U/ml HRP. After recording the fluorescence for 400 s, samples were supplemented with 1 μM rotenone and, after another ~200 s, with 1 μg/ml Antimycin A. The calibration curve was obtained by adding several 100 nmol aliquots of freshly made H$$2$$O$$2$$ to the cuvette containing the respiration buffer, Amplex Ultrared, and HRP. The rate of H$$2$$O$$2$$ emission was expressed in nanomoles of H$$2$$O$$2$$ per milligram of mitochondrial protein per minute.

The rationale for testing mitochondrial ROS generation rate on the flavin adenine dinucleotide (FAD)-linked substrate succinate was based on studies that demonstrated ~300% increase in succinate concentration in the rat brain after ischemia (Folbergrová et al., 1974; Benzi et al., 1979). In contrast, the same ischemia resulted in a profound (8- to 10-fold compared with control) decrease in the concentration of mitochondrial NAD-linked substrates. This elevated cerebral level of succinate returned to the preschismic range by 30 min of reperfusion (Benzi et al., 1982). In mature rats, forebrain ischemia and 6 h of reperfusion resulted in significant inhibition of mitochondrial respiration tested on NAD-linked substrates. However, no significant differences from the control values were found when the same mitochondria respired on succinate (Sims, 1991). In neonatal rats exposed to HI cerebral mitochondria exhibited a better respiration on FAD-linked than on NAD-linked substrates (Gilland et al., 1998). Together, these data indicate that, during postischemic reperfusion in mature and immature brains, the conditions are more preferable for oxidation of succinate rather than NAD-linked substrates.

Reconstitution of isolated C1q$$^+/−$$ mitochondria with exogenous C1q. Reconstitution of isolated C1q$$^+/−$$ mitochondria with exogenous C1q was performed to examine whether direct interaction of hC1q with isolated mitochondria will alter mitochondrial ROS generation rate. Cerebral mitochondria isolated from naive C1q$$^+/−$$ mice (0.1 mg of protein) were coinoculated with either active or heat-inactivated hC1q (1.75 or 3.5 μg/ml) for 30 min at 37°C in 1 ml of cytosol-like buffer (125 mM KCl, 14 mM NaCl, 2 mM KH$$2$$PO$$4$$, 20 mM HEPES, pH 7.2, 1 mM MgCl$$2$$, 4 mM ATP, 0.2 mM EGTA) in the cuvette with magnetic stirrer. At 20 min of incubation, Amplex Ultrasred and 4 U/ml HRP were added and mitochondrial respiration was initiated with supplementation of succinate (5 μM). The H$$2$$O$$2$$ emission rate was recorded for 500 s followed by supplementation of rotenone and antimycin A as described above. After spectrophotometry, mitochondria and buffer containing hC1q were centrifuged at 10,000 × g for 20 min. Then, both supernatant (buffer) and mitochondrial pellet (pellet was washed three times in the fresh buffer) were processed for Western blot analysis for the presence of hC1q.

Membrane potential. The membrane potential ($$\Delta$$Ψ$m$) of isolated mitochondria was estimated using the fluorescence of Saffranin O with excitation and emission wavelengths of 495 and 586 nm, respectively (Kowaltowski et al., 2002). Mitochondria (0.05 mg/ml) were suspended in the respiration buffer supplemented with Saffranin-O at 20:1 ratio (micromolar Saffranin-O to milligrams of mitochondrial protein) to ensure the linearity of the dye response to $$\Delta$$Ψ$m$ changes (Zanotti and Azzone, 1980).

Assessment of mitochondrial ROS scavenging capacity. An assessment of mitochondrial ROS scavenging capacity was based on measurements of total glutathione concentration (GSH), levels of glutathione peroxidase (GPx), glutathione reductase (GR), and Mn-superoxide dismutase (MnSOD) in randomly selected samples of brain mitochondria isolated from C1q$$^+/−$$ and C1q$$^+/+$$ naive mice and HI mice at 4 h of reperfusion.

Measurement of glutathione. GSH concentrations were measured as described by Griffith (1980) with minor modification. Briefly, to prevent self-oxidation, mitochondria (1.5 mg/ml) were diluted in 5% metaphosphoric acid (1:1). Three working solutions were used as follows: (1) 0.3 mM NADPH (Sigma-Aldrich), (2) 6 mM 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) (Sigma-Aldrich), and (3) 10 U/ml glutathione reductase (Sigma-Aldrich). Reduced glutathione in concentration of 0–20 μM was used as standard (Sigma-Aldrich). GSH concentration was measured at 405 nm using a microplate reader (Tecan) and expressed in micromoles per milligram of total protein. The levels of GPx, GR, and MnSOD were quantified by Western blot analysis. Antibodies against GPx, GR, and MnSOD (Abcam) were used in final concentrations of 1:2000, 1:1000, and 1:20000, respectively.

Complex I and citrate synthase activity. Complex I and citrate synthase (CS) activity was measured spectrophotometrically as rotenone-sensitive NADH-E$$\text{Q}$$-reductase. Reaction buffer was composed of 10 ml of 2 mM HEPES, pH 7.8, 75 μM NADH, 40 μM coenzyme Q$$1$$ (final concentration). Frozen-thawed mitochondria (0.1 mg/ml) were mixed with the reaction buffer in a 96-well plate, and the absorbance changes at 340 nm were followed for 15 min with plate reader HTS7000+ (PerkinElmer). In control incubations, the reaction buffer was supplemented with 2 μM rotenone (final concentration). The activity of complex I was calculated as difference between the rates of NADH oxidation (E$$\text{mM}$$ = 6.22 cm$$^{-1}$$) in the absence and in the presence of rotenone and presented in nanomoles of NADH per minute per milligram of protein. CS activity in
0.1 mg/ml mitochondria was measured by the reduction of DTNB as described previously (Shepherd and Garland, 1969).

**Mitochondrial superoxide detection in cells.** Mitochondrial superoxide detection in cells was performed in primary neurons cultured for 3 d in the glass-bottom poly-ν-lysine-coated micro-well dishes (035/10 mm) (MatTek). Cells were seeded at a density of 5 × 10^5. To detect mitochondrial superoxide production, cells were washed with HBSS and incubated with MitoSOX Red (0.2 μM in HBSS, 15 min; Invitrogen) followed by incubation with Hoechst 33342 (0.2 μM in HBSS, 5 min; Invitrogen). MitoSOX Red selectively detects superoxide in the mitochondrial matrix (Kirkland et al., 2007; Robinson et al., 2008). The concentration of MitoSOX (0.2 μM) was selected to avoid cellular toxicity and nonspecific nuclear fluorescence (Simonyan and Skulachev, 1998; Robinson et al., 2008). After incubation with fluoroprobes, cells were washed with HBSS and examined under inverted microscope (Axio Observer Z1; Zeiss). MitoSOX fluorescence was detected using filter (43HE DS-Red; excitation, 563; emission, 581 nm) and Hoechst with the filter (Ste 02; excitation, 365; emission, 420). Images were examined and captured at 37°C using 63× oil objective. The parameters for image capture, fluorescent light intensity and exposure time (500 ms), were set at the initial imaging of C1q−/− naive cells and then kept identical for all other studied samples during each experiment. To minimize photo-oxidation of MitoSOX, the microscopy time for a field selection and adjustment of focus were kept constant (10 s) for all images. For semiquantification of MitoSOX fluorescence, five nonadjacent images (259,840 pixels) per well from each experimental condition were collected and the number of cells (Hoechst-positive nuclei) in each image were counted. The mean value per well represented a single observation (n = 1). Two to four wells per each experimental group were analyzed in each experiment. Data from a total of three separate experiments (three separate neuronal preparations) were analyzed. In neurons after 2–4 h of OGD, the exposure to MitoSOX caused significant cellular mortality and intensive nonspecific nuclear MitoSOX fluorescence. Therefore, the duration of OGD exposure was reduced to 30 min. All images were obtained at 60–70 min of reperfusion. MitoSOX fluorescence was quantified using ImageJ analysis software and expressed in pixels normalized per cell count.

**Electron microscopy.** Electron microscopy of brains in WT mice was performed to examine intraneuronal presence and localization of C1q and expression in pixels normalized per cell count. MitoSOX fluorescence was quantified using ImageJ analysis software. Therefore, the duration of OGD exposure was reduced to 30 min. All images were obtained at 60–70 min of reperfusion. MitoSOX fluorescence was quantified using ImageJ analysis software and expressed in pixels normalized per cell count.

**Figure 1.** A–C, Confocal microscopy for detection of C3b/C3b/C3c (pink) in the contralateral (A), and the ischemic, ipsilateral cortex in WT (B) and C1q−/− (C) HI mice. D, Western blot analysis for C3b content in the contralateral (c) and ipsilateral (l) hemispheres in WT and C1q−/− mice. E–G, Immunostaining for C9 deposition (pink) in the contralateral (E) and ipsilateral cortex in WT (F) and C1q−/− (G) HI mice. The green color is MAP2, and blue is Nissl stain. Scale bars, 50 μm. H–J, Light microscopy images of hippocampus and cortex immunostained for C9 deposition (dark brown) in nonischemic (M) and ipsilateral hemispheres in the vehicle-treated WT mice (J) and their littermates pretreated with CDS59 (J). Scale bars, 100 μm. All data are mean ± SEM. Extent of oxidative brain damage. The extent of oxidative brain damage was analyzed by visual detection and semiquantification of immunopositivity of markers for lipid peroxidation [4-hydroxy-nonenal (4HNE)] and protein peroxynitrosylation [3-nitrotyrosine (3NT)]. In brief, at 4 and 24 h of reperfusion, brains were harvested from randomly selected C1q−/− and age- and strain-matched WT mice, fixed in 4% paraformaldehyde, and soaked in 30% sucrose overnight. The 20-μm-thick coronal sections were blocked (10% donkey serum) and incubated with rabbit polyclonal anti-4-HNE (1:500) and anti-3NT antibodies (1:100) as described previously (Zhu et al., 2007). Samples were examined using Bio-Rad 2000 confocal laser-scanning device attached to a Nikon E800 microscope. The 4-HNE and 3-NT immunoreactivity was analyzed by the count of immunopositive neurons in five nonadjacent fields (40×) of injured cortex at three different bregma levels (−1.0, 0, +1.0 mm). Thus, 15 areas of cortex were analyzed for each mouse and mean value of cell count per square millimeter per mouse was used for statistical analysis. Only those WT and C1q−/− mice that developed signs of neuronal injury (diminished expression of MAP2) were used for data analysis.

**Statistical analysis.** All data were expressed as mean ± SEM. One-way ANOVA or ANOVA for repeated-measures or t test, when appropriate, with Fisher’s post hoc analysis were used to compare the extent of cerebral injury, cellular viability, the degree of C component deposition, and oxidative stress among three or two groups. Data were considered statistically significant if p < 0.05.
C1q+/- littermates (Fig. 2A,B), C1q+/- littermates also demonstrated significantly (p = 0.04) attenuated extent of brain damage compared with their C1q+/- littermates. The distribution of cerebral infarct volumes among C1q+/-, C1q+/-, and C1q+/- littermates was associated with both C1q–protein content in their brains and genotype (Fig. 2B,C). Although mice pretreated with scD59 exhibited significantly decreased deposition of C9 in the injured hemisphere, their cerebral infarct volumes were similar (42 ± 7.4%; n = 6) to the vehicle-treated HI littermates (40 ± 4.87%; n = 6). When C1q-/-, WT, and C6-deficient mice were exposed to hypoxia–ischemia of an identical severity, only C1q-/- mice demonstrated significant neuroprotection (Fig. 2D). In contrast, C6-/- mice demonstrated brain injury to a similar extent as their WT counterparts (Fig. 2D). The serum obtained from these C6-/- HI mice failed to restore MAC-hemolytic activity [5.09 ± 1.6% (C6-/-; n = 4)] vs 63 ± 2.2% (WT; n = 4) hemolysis; p < 0.0001] of the C6-deficient human serum, providing a functional confirmation for C6 deficiency.

### Results

#### Complement is activated in the ischemic brain

At 24 h after hypoxia–ischemia, WT mice demonstrated deposition of C3-split products (C3b/iC3b/C3c) and C9 only in the ischemic (ipsilateral) hemisphere (Fig. 1A,B,E,F,H,I). Western blot analysis revealed markedly increased C3d content in the ipsilateral versus contralateral hemispheres (Fig. 1D). The C-specific immunosignals were detectable in the injured areas of brain defined by the remnant presence or the absence of immunoreactivity for MAP2 (Fig. 1B,F).

#### Genetic ablation of C1q or pretreatment with scD59 attenuates terminal C activation

At 24 h of reperfusion, C1q-/- mice exhibited attenuated deposition and expression of C3-split products and C9 in their injured brains compared with C1q+/- littermates (Fig. 1B,C,F,G). Semiquantitative analysis revealed significantly (p < 0.03) smaller size of the areas immunopositive for C3-split products (7.36 ± 1.87 × 10^3 pixels; n = 4) and C9 (4.8 ± 1.3 × 10^3 pixels; n = 4) in C1q-/- mice compared with their C1q+/- littermates (17 ± 3.6 × 10^3 and 14.2 ± 2.7 × 10^3 pixels, respectively; n = 4). Similarly, Western blot analysis also showed significantly (p < 0.03) decreased C3d/β-actin ratio in the ischemic brains in C1q-/- mice (n = 4) compared with C1q+/- mice (n = 3). Mice pretreated with scD59 compared with their vehicle-treated littermates exhibited significantly (p = 0.01) reduced deposition of C9 (5.2 ± 1.9 × 10^3 vs 31.8 ± 11 × 10^3 pixels; n = 4) in the HI-injured cortex and hippocampus (Fig. 1H–J).

Only C1q-/- mice were protected against hypoxia–ischemia

Analysis of the brain damage revealed a significant (p = 0.0003) decrease of infarct volume in C1q-/- mice compared with their C1q+/- littermates (Fig. 2A,B). C1q+/- littermates also demonstrated significantly (p = 0.04) attenuated extent of brain damage compared with their C1q+/- littermates. The distribution of cerebral infarct volumes among C1q+/-, C1q+/-, and C1q+/- littermates was associated with both C1q–protein content in their brains and genotype (Fig. 2B,C). Although mice pretreated with scD59 exhibited significantly decreased deposition of C9 in the injured hemisphere, their cerebral infarct volumes were similar (42 ± 7.4%; n = 6) to the vehicle-treated HI littermates (40 ± 4.87%; n = 6). When C1q-/-, WT, and C6-deficient mice were exposed to hypoxia–ischemia of an identical severity, only C1q-/- mice demonstrated significant neuroprotection (Fig. 2D). In contrast, C6-/- mice demonstrated brain injury to a similar extent as their WT counterparts (Fig. 2D). The serum obtained from these C6-/- HI mice failed to restore MAC-hemolytic activity [5.09 ± 1.6% (C6-/-; n = 4)] vs 63 ± 2.2% (WT; n = 4) hemolysis; p < 0.0001] of the C6-deficient human serum, providing a functional confirmation for C6 deficiency.

#### C1q accumulates in neuronal cytosol and mitochondria after hypoxia–ischemia

Electron microscopy revealed that, in naive WT mice, neurons constitutively express C1q in the cytosol and mitochondria (0.81 ± 0.42 immunogold particles per organelle) (Fig. 3A). However, in response to hypoxia–ischemia and 12 h of reperfusion, there was a markedly increased presence of C1q in neuronal cytosol associated with significantly increased (4.23 ± 1.82 C1q-immunogold particles per organelle; p < 0.0001) accumulation of C1q in mitochondria (Fig. 3A,B). Of note, 8.76% of mitochondria in HI neurons exhibited very dense (the distance between particles, ~12 nm) accumulation of C1q in the matrix (Fig. 3B,C). Western blot analysis also revealed an increasing presence of C1q in the ipsilateral hemisphere at 3.5 and 7 h of reperfusion, compared with naive mice (supplemental Fig. 1A, available at www.jneurosci.org as supplemental material).

#### C1q ablation limits mitochondrial ROS emission and extent of oxidative brain injury only in neonatal mice

Brain mitochondria isolated from C1q-/- mice exhibited a significantly decreased rate of ROS emission compared with their C1q+/- littermates at all time points, before hypoxia–ischemia (naive mice), at 0, 30–60 min, and 4–6 h after hypoxia–ischemia (Fig. 3D–G). Importantly, in WT HI mice at 0 min of reperfusion, the rate of mitochondrial ROS emission in the brain did not differ from that in their naive littermates (Fig. 3E). However, once reperfusion was established, WT mice demonstrated a robust acceleration in mitochondrial ROS emission rate compared with naive and non-reperfused HI littermates (Fig. 3E). In contrast, C1q-/- HI mice exhibited a significantly lower rate of ROS release at 30–60 min of reperfusion compared with WT counterparts, although it was significantly increased compared with that
at 0 min of reperfusion (Fig. 3E). The C1q<sup>−/−</sup> genotype-associated inhibition in ROS emission rate was detected before and after inhibition of the C-I with rotenone (Rot) and inhibition of the C-III with antimycin A (AntA) (Fig. 3F, G). Remarkably, at 4–6 h of reperfusion, the rate of ROS emission in WT HI mice was diminished compared with that at 30–60 min of reperfusion. At the same time, C1q<sup>−/−</sup> mice mitochondria continued to generate ROS at a rate comparable with that of their naive littermates (Fig. 3E). Of note, no difference in mitochondrial membrane potential was found between C1q<sup>−/−</sup> and C1q<sup>+/+</sup> mice assessed at 0 (data not shown) and 30 min of reperfusion, the time point when ROS emission rate differed the most between two genotypes (supplemental Fig. 1B, available at www.jneurosci.org as supplemental material). At 4 and 24 h of reperfusion, staining of brains for markers of lipid and protein oxidative damage (4HNE and 3NT) revealed significantly attenuated signs of oxidative stress in C1q<sup>−/−</sup> mice compared with WT mice (Fig. 4A–G). The signs of oxidative brain damage were detectable at 4 h of reperfusion with additional magnification by 24 h of reperfusion in mice of both genotypes. This was associated with a gradual loss of the MAP2 immunonegativity, indicating a propagation of cellular damage and death (Fig. 4A–E).

Surprisingly, brain mitochondria isolated from naive adult (10-week-old) C1q<sup>−/−</sup> mice demonstrated the same rate of ROS emission as mitochondria from C1q<sup>+/+</sup> mice (supplemental Fig. 1D–F, available at www.jneurosci.org as supplemental material). This coincided with the absence of neuroprotective effect of C1q gene deletion against HI injury in mature mice (supplemental Fig. 1G,H, available at www.jneurosci.org as supplemental material).

C1q deletion attenuates post-HI inhibition of mitochondrial respiration

At 0 min of reperfusion, mitochondria isolated from the ipsilateral hemisphere of neonatal WT mice demonstrated significant (p = 0.0001) inhibition of phosphorylating and uncoupled respiration along with poorer RCR compared with their naive counterparts (Fig. 5A,B,D). No significant changes in the resting (state 4) respiration rates were detected in HI mice of both genotypes (Fig. 5C). Importantly, at 0 min of reperfusion, cerebral mitochondria from C1q<sup>−/−</sup> mice compared with their WT counterparts exhibited minimally inhibited respiratory chain activity, as defined by ADP-phosphorylating and uncoupled respiration rates (Fig. 5A,B). This was associated with spared C-I activity in C1q<sup>−/−</sup> mice, but not in WT mice in which hypoxia–ischemia caused significant inhibition of C-I (Fig. 5E). At 30–60 min of reperfusion, the rate of mitochondrial O<sub>2</sub> consumption during state 3 respiration was well coupled and fully restored in both groups of mice and did not differ from their naive counterparts (Fig. 5A,B,D). In WT HI mice, this fully restored activity of the mitochondrial respiratory chain was paralleled with the peak in post-HI ROS emission rate detected at 30–60 min of reperfusion.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** A, Electron microscopy of neurons immunostained for C1q with antibodies conjugated with 12 nm immunogold (arrows) in naive and HI mice at 12 h of reperfusion (A). In B, the arrow indicates inset of magnified areas in this and other (C) neurons with characteristic dense accumulation of C1q in mitochondria. Scale bars, 100 nm. M, Mitochondrion. D–F, Representative recording of changes in H<sub>2</sub>O<sub>2</sub>-specific fluorescence measured in cerebral mitochondria isolated from C1q<sup>−/−</sup> and C1q<sup>+/+</sup> mice at 30 min of reperfusion. The arrows indicate supplementation of mitochondria (Mito), rotenone (Rot), and antimycin A (Ant.A). E–G, H<sub>2</sub>O<sub>2</sub> generation rate in mitochondria isolated from C1q<sup>−/−</sup> (black bar) and C1q<sup>+/+</sup> (checkered bar) at different time points after HI insult. Naive mice (n = 11 and 8) at 0 min (n = 4 in both groups), at 30–60 min (n = 8 and 5), and at 4–6 h (n = 7 and 5) of reperfusion. E, Total rate. F is the rate after rotenone supplementation, and G is the rate after antimycin-A supplementation. *p < 0.05 compared with the corresponding WT mice; **p = 0.01 compared with naive and that at 0 min of reperfusion; ***p = 0.02 compared with that measured at 30–60 min of reperfusion in WT mice. Error bars indicate SEM.
C1q immune signal in the neuronal cytosol and mitochondria after 90 min incubation with hC1q (Fig. 5G,H). An incubation of hC1q with isolated C1q$^{-/-}$ mitochondria resulted in hC1q–mitochondria interaction (supplemental Fig. 1B, available at www.jneurosci.org as supplemental material). However, this interaction did not affect mitochondrial ROS emission rate (data not shown).

C1q$^{-/-}$ neurons are protected against OGD and exposure to hC1q abrogates this protection

Cortical C1q$^{-/-}$ neurons demonstrated a dramatic ($p = 0.0007$) protection against OGD challenge compared with their WT counterparts (Fig. 6A). However, when OGD-stressed C1q$^{-/-}$ cells were “reperfused” in the presence of increasing concentrations of hC1q, neuronal viability decreased in the hC1q dose-dependent manner (Fig. 6A). No change in OGD-induced mortality was detected after reperfusion of C1q$^{-/-}$ neurons with heat-inactivated hC1q. Importantly, the deleterious effect of hC1q on cellular survival was fully abrogated in the presence of the ROS scavenger, Trolox (Fig. 6A). The OGD and 60 min of reperfusion significantly increased mitochondrial superoxide-specific fluorosignal only in WT neurons (Fig. 6B,C). In C1q$^{-/-}$ OGD-stressed cells, the MitoSOX fluorescence was significantly reduced compared with that in WT OGD cells (Fig. 6B,C). The exposure to hC1q during 60 min of reperfusion further increased ROS signal in C1q$^{-/-}$ cells, and heat inactivation of hC1q prevented this effect (Fig. 6C).

**Discussion**

Complement is activated in the ischemic brain after hypoxia–ischemia in immature rodents and in human infants (Cowell et al., 2003; Schultz et al., 2005). We also found markers for C activation (C3-split products and C9) only in the post-HI brain. In C1q$^{-/-}$ mice, signs of C activation and deposition of the terminal C complex were significantly decreased, the event associated with neuroprotection against hypoxia–ischemia. This suggests that the neuroprotection in C1q$^{-/-}$ mice is attributable to a limited C activation and assembly of the terminal C complex. However, neither genetic (C6$^{-/-}$ mice) nor pharmacological (pretreatment with scD59) inhibition of the terminal C complex assembly resulted in protection against hypoxia–ischemia. This implies that terminal C complex does not contribute to the HI injury in the developing brain. C1q-mediated C activation pathway generates proinflammatory mediators, C3a and C5a, implicated in the pathogenesis of focal ischemic brain injury (Van Beek et al., 2000; Mocco et al., 2006). The neuroinflammatory response develops within hours and days after hypoxia–ischemia (Ferriero, 2004). In our experiments, C1q$^{-/-}$ mice exhibited signs of neuroprotection (significantly better preserved mitochondrial phosphorylating respiration and DNP accelerated) assessed at the same time point did not differ from that in naive C1q$^{-/-}$ mice (Fig. 5A,B).

**Exposure to C1q increased mitochondrial superoxide only in cultured neurons**

When C1q$^{-/-}$ cortical neurons were exposed to hC1q for 90 min and labeled with MitoSOX, an elevation ($p = 0.06$) of superoxide-specific signal was detected (Fig. 5F). This effect was absent after exposure to a heat-inactivated hC1q (Fig. 5F). Electron microscopy of C1q$^{-/-}$ neurons revealed an appearance of...
and C-I activity) even before the reperfusion, when neuroinflammation cannot be considered. Therefore, it is unlikely that attenuated complement-mediated neuroinflammation accounts for neuroprotection in C1q<sup>-/-</sup> mice.

In C1q-sufficient mice, hypoxia–ischemia and reperfusion were associated with robust accumulation of C1q in the neuronal cytosol and mitochondria. This is consistent with a dramatic overexpression of C1q in the brain after global ischemia (Schäfer et al., 2000) and in neuron-like PC12 cells on hypoxic stress (Tohgi et al., 2000). Although this postischemic up-regulation and accumulation of C1q in the brain can be the initial sign of classical C activation pathway, there is another molecular effect associated with neuronal presence of C1q, accelerated release of ROS from mitochondria. In the absence of C1q, brain mitochondria generated significantly less ROS compared with C1q-sufficient littermates. C1q<sup>-/-</sup> genotype was also associated with significantly better preservation of the mitochondrial phosphorylating and uncoupled respiration and C-I activity at the end of HI insult. This suggests that the absence of C1q protects mitochondrial respiratory chain against inhibition by hypoxia–ischemia. Postischemic inhibition of mitochondrial C-I was suggested as a molecular mechanism responsible for excessive generation of ROS from mitochondrial respiratory chain during reperfusion (Chen et al., 2008). An accelerated ROS emission from cerebral mitochondria in C1q<sup>+/+</sup> HI mice could be explained by a greater C-I inhibition compared with C1q<sup>-/-</sup> HI mice. However, mitochondria obtained from naive C1q<sup>+/+</sup> and C1q<sup>-/-</sup> mice with unaltered C-I activity also exhibited a markedly different rate in ROS emission, pointing to a C-I-independent mechanism for C1q regulation of mitochondrial ROS release. It has been proposed that accelerated mitochondrial ROS emission after global brain ischemia is responsible for inactivation of respiratory chain complexes, including C-I (Racey et al., 2009). Therefore, the relative resistance of C-I toward an inhibiting effect of hypoxia–ischemia in C1q<sup>-/-</sup> HI mice could be secondary to a limited acceleration in ROS emission during HI insult so that ROS levels in the mitochondrial matrix do not reach a threshold to cause C-I dysfunction. Neuronal mitochondria were shown to respond with a burst of ROS release within minutes of initiation of OGD. By the end of OGD challenge, mitochondrial emission of ROS declined secondary to collapsed ΔΨ<sub>m</sub> (Abramov et al., 2007). Importantly, a difference in ΔΨ<sub>m</sub>, a well established regulator of mitochondrial ROS production rate (Starkov and Fiskum, 2003), cannot account for the difference in mitochondrial ROS emission in C1q<sup>+/+</sup> versus C1q<sup>-/-</sup> mice, as ΔΨ<sub>m</sub> did not differ between mice of these genotypes. We also found no difference in the mitochondrial total GSH content or the presence of GPx, GR, and MnSOD in mitochondria isolated from C1q<sup>-/-</sup> and C1q<sup>+/+</sup> naive or HI mice (supplemental
origin contribute to oxidative injury in HI brain. In C1q−/− mice, signs of oxidative injury coincided (4 h of reperfusion) with mitochondrial signs of a secondary energy failure (4–6 h of reperfusion), evidenced by the secondary decline of phosphorylating respiration rates. We propose that, in immature brain, C1q amplifies a burst of mitochondrial ROS release during hypoxia–ischemia and reperfusion, and exacerbates oxidative brain injury, leading to a greater inhibition of mitochondrial respiratory chain. The data obtained in adult C1q−/− and C1q−/+ mice serve as an argumentum a contrario for this hypothetical sequence of events. Brain mitochondria isolated from adult C1q−/− and C1q−/+ mice exhibited similar rates of ROS emission, and mature C1q−/− mice were not protected against HI injury. This suggests that the ability of C1q to exacerbate oxidative stress by accelerating mitochondrial ROS emission is developmentally regulated. Wang et al. (2009) recently reported a fundamental age-dependent difference in the role of mitochondrial permeability transition pore in propagation of apoptotic and necrotic neuronal death after hypoxia–ischemia.

Interestingly, in 8.76% of neuronal mitochondria examined after HI insult, C1q protein accumulated at a very high density. When isolated C1q−/− mitochondria were coincubated with hC1q, Western blot analysis revealed redistribution of hC1q from the buffer to mitochondria. However, no changes were detected in the ROS emission rate. This suggests that direct interaction between mitochondria and hC1q exists; however, it requires an additional intracellular signaling to alter ROS generation. Thus, the significance for cellular fate of this relatively minor (8.76%) fraction of mitochondria with dense C1q accumulation remains unclear. Of note, the fraction of mitochondria that released apoptosis-inducing factor after hypoxia–ischemia did not exceed 20% in P5 and 10% in P21 mice (Zhu et al., 2005), suggesting that the damage of only 10–20% of mitochondria is sufficient for execution of cellular death pathway after hypoxia–ischemia.

Our in vitro experiments support detrimental role of C1q-mediated mitochondrial ROS release in HI brain injury. In C1q−/+ cells, OGD challenge increased mitochondrial ROS signal associated with significant cellular mortality, and the exposure to antioxidant, Trolox, improved cellular viability. Compared with C1q−/+ cells, C1q−/− neurons exhibited a markedly reduced mitochondrial ROS signal coupled with significantly better viability after OGD. When during reperfusion the C1q−/− neurons were exposed to hC1q, cells exhibited a dose-dependent increase in their mortality rate, virtually turning C1q−/− phenotype into C1q−/+ phenotype with respect to OGD-induced mortality.

Fig. 1 I–K, available at www.jneurosci.org as supplemental material). Thus, neither mitochondrial ROS scavenging capacity nor ΔΨm account for the significantly decreased rate of mitochondrial ROS emission in C1q−/− mice compared with C1q−/+ counterparts. Although we do not know the exact molecular mechanism for C1q-mediated regulation of mitochondrial ROS release, this study is the first to demonstrate a pathophysiological significance of C1q in oxidative stress originated from mitochondria during HI damage in the developing brain. Compared with C1q−/+ mice, C1q−/− mice exhibited significantly reduced extent of oxidative injury, suggesting that ROS of mitochondrial origin contribute to oxidative injury in HI brain. In C1q−/− mice, signs of oxidative injury coincided (4 h of reperfusion) with mitochondrial signs of a secondary energy failure (4–6 h of reperfusion), evidenced by the secondary decline of phosphorylating respiration rates. We propose that, in immature brain, C1q amplifies a burst of mitochondrial ROS release during hypoxia–ischemia and reperfusion, and exacerbates oxidative brain injury, leading to a greater inhibition of mitochondrial respiratory chain. The data obtained in adult C1q−/− and C1q−/+ mice serve as an argumentum a contrario for this hypothetical sequence of events. Brain mitochondria isolated from adult C1q−/− and C1q−/+ mice exhibited similar rates of ROS emission, and mature C1q−/− mice were not protected against HI injury. This suggests that the ability of C1q to exacerbate oxidative stress by accelerating mitochondrial ROS emission is developmentally regulated. Wang et al. (2009) recently reported a fundamental age-dependent difference in the role of mitochondrial permeability transition pore in propagation of apoptotic and necrotic neuronal death after hypoxia–ischemia.

Interestingly, in 8.76% of neuronal mitochondria examined after HI insult, C1q protein accumulated at a very high density. When isolated C1q−/− mitochondria were coincubated with hC1q, Western blot analysis revealed redistribution of hC1q from the buffer to mitochondria. However, no changes were detected in the ROS emission rate. This suggests that direct interaction between mitochondria and hC1q exists; however, it requires an additional intracellular signaling to alter ROS generation. Thus, the significance for cellular fate of this relatively minor (8.76%) fraction of mitochondria with dense C1q accumulation remains unclear. Of note, the fraction of mitochondria that released apoptosis-inducing factor after hypoxia–ischemia did not exceed 20% in P5 and 10% in P21 mice (Zhu et al., 2005), suggesting that the damage of only 10–20% of mitochondria is sufficient for execution of cellular death pathway after hypoxia–ischemia.

Our in vitro experiments support detrimental role of C1q-mediated mitochondrial ROS release in HI brain injury. In C1q−/+ cells, OGD challenge increased mitochondrial ROS signal associated with significant cellular mortality, and the exposure to antioxidant, Trolox, improved cellular viability. Compared with C1q−/+ cells, C1q−/− neurons exhibited a markedly reduced mitochondrial ROS signal coupled with significantly better viability after OGD. When during reperfusion the C1q−/− neurons were exposed to hC1q, cells exhibited a dose-dependent increase in their mortality rate, virtually turning C1q−/− phenotype into C1q−/+ phenotype with respect to OGD-induced mortality.

Fig. 1 I–K, available at www.jneurosci.org as supplemental material). Thus, neither mitochondrial ROS scavenging capacity nor ΔΨm account for the significantly decreased rate of mitochondrial ROS emission in C1q−/− mice compared with C1q−/+ counterparts. Although we do not know the exact molecular mechanism for C1q-mediated regulation of mitochondrial ROS release, this study is the first to demonstrate a pathophysiological significance of C1q in oxidative stress originated from mitochondria during HI damage in the developing brain. Compared with C1q−/+ mice, C1q−/− mice exhibited significantly reduced extent of oxidative injury, suggesting that ROS of mitochondrial origin contribute to oxidative injury in HI brain. In C1q−/− mice, signs of oxidative injury coincided (4 h of reperfusion) with mitochondrial signs of a secondary energy failure (4–6 h of reperfusion), evidenced by the secondary decline of phosphorylating respiration rates. We propose that, in immature brain, C1q amplifies a burst of mitochondrial ROS release during hypoxia–ischemia and reperfusion, and exacerbates oxidative brain injury, leading to a greater inhibition of mitochondrial respiratory chain. The data obtained in adult C1q−/− and C1q−/+ mice serve as an argumentum a contrario for this hypothetical sequence of events. Brain mitochondria isolated from adult C1q−/− and C1q−/+ mice exhibited similar rates of ROS emission, and mature C1q−/− mice were not protected against HI injury. This suggests that the ability of C1q to exacerbate oxidative stress by accelerating mitochondrial ROS emission is developmentally regulated. Wang et al. (2009) recently reported a fundamental age-dependent difference in the role of mitochondrial permeability transition pore in propagation of apoptotic and necrotic neuronal death after hypoxia–ischemia.

Interestingly, in 8.76% of neuronal mitochondria examined after HI insult, C1q protein accumulated at a very high density. When isolated C1q−/− mitochondria were coincubated with hC1q, Western blot analysis revealed redistribution of hC1q from the buffer to mitochondria. However, no changes were detected in the ROS emission rate. This suggests that direct interaction between mitochondria and hC1q exists; however, it requires an additional intracellular signaling to alter ROS generation. Thus, the significance for cellular fate of this relatively minor (8.76%) fraction of mitochondria with dense C1q accumulation remains unclear. Of note, the fraction of mitochondria that released apoptosis-inducing factor after hypoxia–ischemia did not exceed 20% in P5 and 10% in P21 mice (Zhu et al., 2005), suggesting that the damage of only 10–20% of mitochondria is sufficient for execution of cellular death pathway after hypoxia–ischemia.

Our in vitro experiments support detrimental role of C1q-mediated mitochondrial ROS release in HI brain injury. In C1q−/+ cells, OGD challenge increased mitochondrial ROS signal associated with significant cellular mortality, and the exposure to antioxidant, Trolox, improved cellular viability. Compared with C1q−/+ cells, C1q−/− neurons exhibited a markedly reduced mitochondrial ROS signal coupled with significantly better viability after OGD. When during reperfusion the C1q−/− neurons were exposed to hC1q, cells exhibited a dose-dependent increase in their mortality rate, virtually turning C1q−/− phenotype into C1q−/+ phenotype with respect to OGD-induced mortality.

Our in vitro experiments support detrimental role of C1q-mediated mitochondrial ROS release in HI brain injury. In C1q−/+ cells, OGD challenge increased mitochondrial ROS signal associated with significant cellular mortality, and the exposure to antioxidant, Trolox, improved cellular viability. Compared with C1q−/+ cells, C1q−/− neurons exhibited a markedly reduced mitochondrial ROS signal coupled with significantly better viability after OGD. When during reperfusion the C1q−/− neurons were exposed to hC1q, cells exhibited a dose-dependent increase in their mortality rate, virtually turning C1q−/− phenotype into C1q−/+ phenotype with respect to OGD-induced mortality.
This deleterious effect of hC1q on neuronal viability in OGD-exposed C1q−/− cells was fully abrogated by Trolox. Trolox is a vitamin E derivative used extensively in vitro and in vivo to dissect out the contribution of oxidative stress from other mechanisms of ischemic neuronal injury (Copin et al., 1998; Gupta and Sharma, 2006; Wang et al., 2008). Interestingly, the measurement of mitochondrial superoxide-specific signal in naïve neurons did not demonstrate statistical significance between C1q−/− and WT cells. However, in response to OGD, C1q−/− cells exhibited significantly decreased mitochondrial superoxide fluorescence compared with OGD-stressed WT neurons. The difference in ROS emission rates between WT and C1q−/− isolated mitochondria was detected using the FAD-linked substrate succinate. It is important to note that the difference in mitochondrial ROS signal was reproduced in WT and C1q−/− live neurons only after OGD challenge. This suggests that, during reperfusion, neurons more actively oxidize succinate than NAD-linked substrates. It has been reported that brain ischemia and reperfusion in rats resulted in significant inhibition of mitochondrial respiration tested on NAD-linked substrates. However, no significant differences from the control values were detected when the same mitochondria expired on succinate (Sims, 1991). Similarly, in neonatal rats exposed to hypoxia–ischemia, cerebral mitochondria exhibited a better respiration on FAD-linked than on NAD-linked substrates (Gillard et al., 1998). This suggests that, compared with the C-I activity, the activity of C-II is better preserved after hypoxia–ischemia, which makes succinate a preferred mitochondrial substrate on reperfusion. Importantly, succinate oxidation can support the highest rate of ROS production in mitochondria (for review, see Starkov, 2008). Specifically, only mitochondria isolated from the brain and the heart (not liver, kidney, or muscle) exhibit 10-fold increase in ROS emission rates obtained on succinate compared with glutamate, α-ketoglutarate, glycerol phosphate, and palmitate carnitine (Tahara et al., 2009). Theoretically, mitochondria actively oxidizing succinate on reperfusion are capable of a dramatic increase in ROS-generating capacity leading to a reperfusion-driven oxidative burst.

In conclusion, this study uncovers the existence of a novel C1q-dependent pathway in regulation of mitochondrial production of ROS and oxidative stress in the developing brain subjected to hypoxia–ischemia. The central role of C1q in this pathway highlights a mechanistic link between two fundamental events initiated by ischemia–reperfusion: activation of innate immunity and oxidative stress. This study also shows that the classical C activation pathway does not exacerbate HI brain injury via activation of the terminal complex. Finally, this work not only uncovered C1q-dependent mechanism of oxidative damage in the developing brain but also dissected out a causative role for ROS of mitochondrial origin.

References


Mocco J, Mack WJ, Ducrut AF, Sosunov SA, Sughrue ME, Hassid BG, Nair MN, Lauer I, Konotar RJ, Claire M, Holland H, Pinsky DJ, Connolly ES
Ten et al. • C1q Complement and Oxidative Brain Injury


